封面
市场调查报告书
商品编码
1448396

全球癌症疼痛市场规模、份额、成长分析(按药物、适应症划分)- 2024-2031 年产业预测

Global Cancer Pain Market Size, Share, Growth Analysis, By Drug(Opioids, Morphine), By Disease Indication(Lung Cancer, Colorectal Cancer) - Industry Forecast 2024-2031

出版日期: | 出版商: SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格
简介目录

2022年全球癌症疼痛市场规模将为65.5亿美元,从2023年的69.2亿美元成长到2031年的107亿美元,在预测期间(2024-2031年)预计复合年增长率为5.6%。

由于受癌症影响的人数不断增加、人口老化、医疗保健投入增加,全球癌症疼痛市场正在成长,部分原因是护理公司正在进行更多研究。例如,根据美国癌症协会的数据,2020 年,美国约有 180 万新发癌症病例,约 606,520 人死于癌症。根据国际癌症研究机构统计,当年全球约有 1,065,960 人新诊断出罹患大肠癌。由于老龄化对身体和基因变化的影响,老年人更容易罹患癌症。根据美国国家癌症研究所的数据,乳癌的平均诊断年龄为 61 岁,大肠癌的平均诊断年龄为 68 岁,肺癌的平均诊断年龄为 70 岁,而摄护腺癌的平均诊断年龄为 66 岁。

目录

执行摘要

  • 市场概况
  • 命运之轮

调查方法

  • 资讯采购
  • 次要/一级资讯来源
  • 市场规模估算
  • 市场假设与限制

母市场分析

  • 市场概况
  • 市场规模
  • 市场动态
    • 促进因素
    • 机会
    • 抑制因素
    • 任务

主要市场考察

  • 技术分析
  • 价格分析
  • 供应链分析
  • 价值链分析
  • 市场生态系统
  • 智慧财产权分析
  • 贸易分析
  • Start-Ups分析
  • 原料分析
  • 创新矩阵
  • 研发线产品分析
  • 总体经济指标
  • 主要投资分析
  • 关键成功因素
  • 竞争程度

市场动态及展望

  • 市场动态
    • 促进因素
    • 机会
    • 抑制因素
    • 任务
  • 监管环境
  • 波特的分析
  • 对未来中断的特殊考虑

全球癌症疼痛市场:依药物分类

  • 市场概况
  • 阿片类药物
  • 氢可酮
  • Fentanyl
  • 非阿片类药物
  • 乙酰胺酚
  • 非类固醇消炎剂(NSAID)
  • 阻断剂
  • 其他的

全球癌痛市场:依适应症分类

  • 市场概况
  • 肺癌
  • 大肠直肠癌
  • 乳癌
  • 摄护腺癌
  • 血癌
  • 其他的

全球癌症疼痛市场规模:按地区划分

  • 市场概况
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 其他欧洲国家地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地区
  • 中东和非洲 (MEA)
    • 海湾合作委员会国家
    • 南非
    • 其他中东/非洲地区

竞争格局

  • 前5名企业对比
  • 主要企业市场定位(2021年)
  • 主要市场参与者所采取的策略
  • 关键成功策略
  • 近期市集活动
  • 主要企业市场占有率(2021年)

主要企业简介

  • Pfizer(USA)
  • Johnson & Johnson(USA)
  • Purdue Pharma(USA)
  • Novartis(Switzerland)
  • Heron Therapeutics(USA)
  • Teva Pharmaceutical Industries(Israel)
  • Eli Lilly and Company(USA)
  • AstraZeneca(UK)
  • GlaxoSmithKline(UK)
  • Merck & Co., Inc.(USA)
简介目录
Product Code: SQMIG35J2075

Global Cancer Pain Market size was valued at USD 6.55 billion in 2022 and is poised to grow from USD 6.92 billion in 2023 to USD 10.70 billion by 2031, growing at a CAGR of 5.6% in the forecast period (2024-2031).

The global cancer pain market is growing because there are more people getting cancer, the population is getting older, more money is being spent on healthcare, and healthcare companies are doing more research. For example, in 2020, the American Cancer Society said there were about 1.8 million new cases of cancer and around 606,520 people died from cancer in the U.S. That same year, there were about 1,065,960 new cases of colorectal cancer worldwide, according to the International Agency for Research on Cancer. Older people are more likely to get cancer because of how aging affects the body and changes in genes. The National Cancer Institute says the average age for diagnosing breast cancer is 61, colorectal cancer is 68, lung cancer is 70, and prostate cancer is 66.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Pain Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Pain Market Segmental Analysis

The global cancer pain market is segmented on the basis of drug type, disease indication, region. By drug type, the market is segmented into opioids, morphine, fentanyl, others, non-opioids, acetaminophen, non-steroidal anti-inflammatory drugs (nsaids), nerve blockers. By disease indication, the market is segmented into lung cancer, colorectal cancer, breast cancer, prostate cancer, blood cancer, others. By region, the market is segmented into North America, Europe, Latin America, Asia- Pacific, Middle East and Africa.

Drivers of the Global Cancer Pain Market

New ways of managing pain, better ways to give medicine, and treatments made just for each person are making cancer pain management work better and be easier to get to.

Restraints in the Global Cancer Pain Market

The possibility of getting used to a drug, needing it more, and having side effects from pain medicines can stop the market from growing.

Market Trends of the Global Cancer Pain Market

More attention is being put on treating each person differently based on their genes and molecules, which is changing how cancer pain is managed.

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global Cancer Pain Market by Drug

  • Market Overview
  • Opioids
  • Morphine
  • Fentanyl
  • Others
  • Non-opioids
  • Acetaminophen
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Nerve Blockers

Global Cancer Pain Market by Disease Indication

  • Market Overview
  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Blood Cancer
  • Others

Global Cancer Pain Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021

Key Company Profiles

  • Pfizer (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Purdue Pharma (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Heron Therapeutics (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical Industries (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (USA0
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments